<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284464</url>
  </required_header>
  <id_info>
    <org_study_id>EVITAESTEROIDE-12</org_study_id>
    <nct_id>NCT02284464</nct_id>
  </id_info>
  <brief_title>Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients</brief_title>
  <official_title>Steroid Withdrawal and Novo Donor-specific Anti-HLA Antibodies in Renal Transplant Patients: a Prospective, Randomized and Controlled Study in Parallel Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Andaluza de Trasplantes de Organos y Tejidos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Steroids are one of the pillars of immunosuppression for kidney transplant patients but their
      use is associated with a high rate of complications. Withdrawal of steroids reduces some
      metabolic and cardiovascular complications, but it may increase the risk of acute rejection.
      However, little is known about whether steroid withdrawal is associated with the generation
      of anti-HLA donor-specific antibodies (DSA) and the relation between DSA and clinical and
      histological data. The aim of this study is to compare the incidence of de novo anti-HLA DSA
      in stable kidney transplant patients after withdrawing the steroids 3 months after the
      transplantation as compared with patients who continue with steroids. The hypothesis is that
      steroid withdrawal will increase the presence of de novo anti-HLA DSA in stable kidney
      transplant patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of kidney transplant patients with DSA</measure>
    <time_frame>24 months</time_frame>
    <description>Measurements of DSA at baseline, and at 3, 6, 12, 18 and 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial fibrosis and tubular atrophy in both groups as well as vascular lesions in the graft.treatment groups</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement at 3 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection lesions</measure>
    <time_frame>24 months</time_frame>
    <description>Acute rejection lesions (including subclinical rejection) at 12 and 24 months according to Banff 2013 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes mellitus</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of diabetes mellitus after kidney transplant in both groups at 1, 2, 3, 4, 6, 9, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dyslipidemia</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of dyslipidemia after kidney transplant in both groups at 1, 2, 3, 4, 6, 9, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertension</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of hypertension after kidney transplant in both groups at 1, 2, 3, 4, 6, 9, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>24 months</time_frame>
    <description>Renal function after kidney transplant in both groups at 1, 2, 3, 4, 6, 9, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the adherence to immunosuppressive therapy in the two treatment groups and its impact on the generation of DSA</measure>
    <time_frame>At 3, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>24 months</time_frame>
    <description>Patient survival after kidney transplant in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>24 months</time_frame>
    <description>Graft survival after kidney transplant in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Other Complication of Kidney Transplant</condition>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Steroids, tacrolimus and mycophenolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus and mycophenolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone withdrawal</intervention_name>
    <description>Withdrawal of steroids</description>
    <arm_group_label>Tacrolimus and mycophenolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone continuation</intervention_name>
    <description>Continuation of steroids</description>
    <arm_group_label>Steroids, tacrolimus and mycophenolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged over 18 years with no immunological risk (PRA &lt;25% and
             no DSA) who are receiving their first cadaveric or living kidney transplant.

          2. Patients who, three months after the transplantation, are receiving tacrolimus in
             combination with mycophenolic acid (MPA) or mycophenolate mofetil (MMF) plus steroids,
             with stable plasma levels of tacrolimus.

          3. No clinical or histological immunological dysfunction before randomization

          4. No de novo anti-HLA DSA at the time of randomization.

          5. Patients who wish to and are able to give written informed consent to participate in
             the study.

          6. For women, agreeing to use efficient contraception during the study.

        Exclusion Criteria:

          1. Patients who receive a multiorgan transplant.

          2. Retransplants.

          3. Presence of DSA before the transplant or at the time of randomization.

          4. Cold ischemia time &gt;30 hours

          5. Patients with serum creatinine &gt;2 mg/dL or proteinuria &gt;1g/day at the time of
             randomization

          6. Prior episode of severe rejection (II-B-III in the Banff/13 classification) prior to
             randomization.

          7. Presence of subclinical rejection or borderline lesions on the protocol biopsy prior
             to randomization

          8. Patients with BK-polyomavirus nephropathy at the time of randomization.

          9. Patients with recurrent or de novo glomerulonephritis.

         10. Patients who are being treated with immunosuppressive drugs other than those in the
             randomized clinical trial in question.

         11. Patients who are positive for the human immunodeficiency virus (HIV) or those who have
             a severe systemic infection that, in the investigator's judgment, will require
             continued treatment.

         12. Patients with any present or prior (during the previous 5 years) malignant disease,
             except basal or squamous cell carcinoma that has been excised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domingo Hernandez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carlos Haya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Domingo Hernandez, PhD</last_name>
    <phone>+34 951291174</phone>
    <email>domingohernandez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pedro Ruiz, MsC</last_name>
    <phone>+34 951291174</phone>
    <email>pedro_ruiz_esteban@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vall d Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joana Sellares, MD</last_name>
      <phone>+34 932746079</phone>
      <email>jsellares@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Joana Sellares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carlos Haya Hospital</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domingo Hernandez, PhD</last_name>
      <phone>+34 951291174</phone>
      <email>domingohernandez@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pedro Ruiz, MsC</last_name>
      <phone>+34 951291174</phone>
      <email>pedro_ruiz_esteban@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Domingo Hernandez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abelardo Caballero, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Garcia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edisson Rudas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Ruiz, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canarias University Hospital</name>
      <address>
        <city>Tenerife</city>
        <zip>38200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Angeles Cobo, PhD</last_name>
      <phone>+34 922678000</phone>
      <email>mcobcas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Angeles Cobo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002 Oct;2(9):807-18. Review.</citation>
    <PMID>12392286</PMID>
  </reference>
  <reference>
    <citation>Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009 Nov 12;69(16):2227-43. doi: 10.2165/11319260-000000000-00000. Review.</citation>
    <PMID>19852526</PMID>
  </reference>
  <reference>
    <citation>Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J; FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008 Feb;8(2):307-16. doi: 10.1111/j.1600-6143.2007.02057.x. Erratum in: Am J Transplant.2008 May;8(5):1080.</citation>
    <PMID>18211506</PMID>
  </reference>
  <reference>
    <citation>Arnol M, de Mattos AM, Chung JS, Prather JC, Mittalhenkle A, Norman DJ. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation. 2008 Dec 27;86(12):1844-8. doi: 10.1097/TP.0b013e31818ffec0.</citation>
    <PMID>19104432</PMID>
  </reference>
  <reference>
    <citation>Opelz G, Döhler B. Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant. 2013 Aug;13(8):2096-105. doi: 10.1111/ajt.12313. Epub 2013 Jun 10.</citation>
    <PMID>23750878</PMID>
  </reference>
  <reference>
    <citation>Opelz G, Döhler B, Laux G; Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005 Apr;5(4 Pt 1):720-8.</citation>
    <PMID>15760395</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Molina M, Gentil MA, Burgos D, Cabello M, Cobelo C, Bustamante J, Errasti P, Franco A, Hernández D. Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study. NDT Plus. 2010 Jun;3(Suppl_2):ii32-ii36.</citation>
    <PMID>20508858</PMID>
  </reference>
  <reference>
    <citation>Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000 Oct;11(10):1910-7.</citation>
    <PMID>11004223</PMID>
  </reference>
  <reference>
    <citation>Pascual J, Quereda C, Zamora J, Hernández D; Spanish Group for Evidence-Based Medicine in Renal Transplantation. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation. 2004 Nov 27;78(10):1548-56.</citation>
    <PMID>15599321</PMID>
  </reference>
  <reference>
    <citation>Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008 Oct;248(4):564-77. doi: 10.1097/SLA.0b013e318187d1da.</citation>
    <PMID>18936569</PMID>
  </reference>
  <reference>
    <citation>Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004 Mar;4(3):438-43.</citation>
    <PMID>14961999</PMID>
  </reference>
  <reference>
    <citation>Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012 May;12(5):1157-67. doi: 10.1111/j.1600-6143.2012.04013.x. Epub 2012 Mar 19.</citation>
    <PMID>22429309</PMID>
  </reference>
  <reference>
    <citation>Gill JS, Landsberg D, Johnston O, Shapiro RJ, Magil AB, Wu V, Tinckam K, Keown P. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation. 2010 Jan 27;89(2):178-84. doi: 10.1097/TP.0b013e3181c3503e.</citation>
    <PMID>20098280</PMID>
  </reference>
  <reference>
    <citation>Cantarovich D, De Amicis S, Akl A, Devys A, Vistoli F, Karam G, Soulillou JP. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant. 2011 Dec;11(12):2737-46. doi: 10.1111/j.1600-6143.2011.03729.x. Epub 2011 Sep 11.</citation>
    <PMID>21906255</PMID>
  </reference>
  <reference>
    <citation>Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation. 2012 Jun 15;93(11):1173-8. doi: 10.1097/TP.0b013e31824f3d7c.</citation>
    <PMID>22592887</PMID>
  </reference>
  <reference>
    <citation>Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003 Apr 15;75(7):1034-40.</citation>
    <PMID>12698094</PMID>
  </reference>
  <reference>
    <citation>Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, Rebellato L. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007 Apr;7(4):864-71.</citation>
    <PMID>17391129</PMID>
  </reference>
  <reference>
    <citation>Moreso F, Ibernon M, Gomà M, Carrera M, Fulladosa X, Hueso M, Gil-Vernet S, Cruzado JM, Torras J, Grinyó JM, Serón D. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant. 2006 Apr;6(4):747-52.</citation>
    <PMID>16539631</PMID>
  </reference>
  <reference>
    <citation>Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.</citation>
    <PMID>18773960</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Steroid withdrawal</keyword>
  <keyword>Donor specific antibodies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

